[go: up one dir, main page]

NO975367L - New variants of apolipoprotein A-I - Google Patents

New variants of apolipoprotein A-I

Info

Publication number
NO975367L
NO975367L NO975367A NO975367A NO975367L NO 975367 L NO975367 L NO 975367L NO 975367 A NO975367 A NO 975367A NO 975367 A NO975367 A NO 975367A NO 975367 L NO975367 L NO 975367L
Authority
NO
Norway
Prior art keywords
apolipoprotein
new variants
variants
new
Prior art date
Application number
NO975367A
Other languages
Norwegian (no)
Other versions
NO975367D0 (en
Inventor
Gerd Assmann
Patrick Benoit
Eric Bruckert
Patrice Denefle
Nicolas Duverger
Jean-Charles Fruchart
Gerald Luc
Gerard Turpin
Harald Funke
Original Assignee
Rhone Poulenc Rorer Sa
Pasteur Institut
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Pasteur Institut, Univ Paris Curie filed Critical Rhone Poulenc Rorer Sa
Publication of NO975367D0 publication Critical patent/NO975367D0/en
Publication of NO975367L publication Critical patent/NO975367L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO975367A 1995-05-22 1997-11-21 New variants of apolipoprotein A-I NO975367L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (en) 1995-05-22 1995-05-22 NEW VARIANTS OF APOLIPOPROTEIN
PCT/FR1996/000747 WO1996037608A1 (en) 1995-05-22 1996-05-20 Novel variants of apolipoprotein a-i

Publications (2)

Publication Number Publication Date
NO975367D0 NO975367D0 (en) 1997-11-21
NO975367L true NO975367L (en) 1997-11-21

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975367A NO975367L (en) 1995-05-22 1997-11-21 New variants of apolipoprotein A-I

Country Status (16)

Country Link
EP (1) EP0827538A1 (en)
JP (1) JPH11505712A (en)
KR (1) KR19990021828A (en)
AU (1) AU717202B2 (en)
BR (1) BR9608813A (en)
CA (1) CA2218759A1 (en)
CZ (1) CZ291376B6 (en)
FR (1) FR2734568B1 (en)
HU (1) HUP9802926A3 (en)
IL (1) IL118336A0 (en)
MX (1) MX9708727A (en)
NO (1) NO975367L (en)
SK (1) SK156397A3 (en)
TW (1) TW434260B (en)
WO (1) WO1996037608A1 (en)
ZA (1) ZA964097B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CA2402772A1 (en) * 2000-03-13 2001-09-20 Amgen Inc. Apolipoprotein-a-i regulation of t-cell signalling
AU2002213843B2 (en) 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
WO2003026492A2 (en) 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
JP4777873B2 (en) 2003-02-14 2011-09-21 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Lipophilic drug delivery vehicles and methods of use thereof
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
KR100560102B1 (en) 2004-06-25 2006-03-13 한국생명공학연구원 Proapolipoprotein A-I variants and antilipidemia or arteriosclerosis comprising the same
WO2006012632A2 (en) * 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
KR100725642B1 (en) * 2006-01-20 2007-06-07 충남대학교산학협력단 Peptides Antioxidant Against Low Density Lipoproteins
WO2007137400A1 (en) 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
RU2604489C2 (en) * 2008-10-03 2016-12-10 КьюРНА,Инк.,US Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
PL2396017T3 (en) 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
CN103443123B (en) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 Lipoprotein complex and its preparation and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (en) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.

Also Published As

Publication number Publication date
KR19990021828A (en) 1999-03-25
AU5904896A (en) 1996-12-11
HUP9802926A3 (en) 2001-08-28
IL118336A0 (en) 1996-09-12
CZ367197A3 (en) 1998-03-18
ZA964097B (en) 1996-12-06
JPH11505712A (en) 1999-05-25
WO1996037608A1 (en) 1996-11-28
BR9608813A (en) 1999-02-17
CA2218759A1 (en) 1996-11-28
TW434260B (en) 2001-05-16
AU717202B2 (en) 2000-03-23
MX9708727A (en) 1997-12-31
NO975367D0 (en) 1997-11-21
EP0827538A1 (en) 1998-03-11
SK156397A3 (en) 1998-07-08
CZ291376B6 (en) 2003-02-12
FR2734568A1 (en) 1996-11-29
FR2734568B1 (en) 1997-06-20
HUP9802926A2 (en) 1999-03-29

Similar Documents

Publication Publication Date Title
NO975367D0 (en) New variants of apolipoprotein A-I
NO982809L (en) Drugs of thrombin inhibitors
DE69623302D1 (en) SECTION MILLING OF HOLES
DE69634998D1 (en) Control of edges
NO975159L (en) Method of controlling biodegradation
BR9609726A (en) Inhibition of gene expression
FI971784A0 (en) Inhibitors of apolipoprotein B synthesis
DE69622933D1 (en) Prodrugs of paclitaxel derivatives
EE04241B1 (en) Inhibitors of apolipoprotein B synthesis
NO940912L (en) Purification of refrigerant
FR2731885B1 (en) INSTALLATION OF REMOVABLE SHELVES
EP0801574A4 (en) REGULATION OF INTEGRIN MEDIATED SIGNAL FORWARDING
NO973203L (en) New applications of lysozyme dimers
DE69605202D1 (en) PRODUCTION OF ALPHA-TOCOPHEROL
DE69623986D1 (en) Production of allomelanin
FI942576A0 (en) Behandling of plasma
NO974995D0 (en) Esters of carbapenems
NO974966D0 (en) New applications of heptafluoropropane
NO941809L (en) Asymmetric hydrogenation of furoimidazole derivatives
NO974994D0 (en) Esters of carbapenems
KR970048178U (en) Pseudostereo signal controller of television
KR960027486U (en) Rotating structure of lighting
KR970011853U (en) New form of maryas
FI954927A0 (en) Foerfarande Foer elimination of utslaepp i innerluft och anordning haerfoer
KR970020819U (en) Gap control structure of dishwasher

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application